Biotechnology

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

A new alliance of 21 biotech firms aims to forge a national strategy, warning that America's long-held lead in medical innovation is under pressure.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With its 100th study launch and a perfect client retention rate, Atreo's agile RTSM platform is challenging the rigid, slow pace of traditional trial tech.

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

Germany's startups attracted €1.7B in Q1 2026, fueled by US investors and a massive bet on artificial intelligence, signaling a new era for its ecosystem.

A novel gene therapy aims to cross the blood-brain barrier, offering new hope for Tuberous Sclerosis Complex, thanks to a powerful new partnership.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

Jeito Capital appoints top talent and BD partners, signaling a strategic shift in biopharma investing where deep operational expertise is now king.

A new drug, CS-1103, earns FDA Fast Track to combat fentanyl overdoses by binding and removing the opioid, a potential game-changer over naloxone.

A new 'dream team' of experts will guide AI development to create non-invasive tools for a deadly lung disease, aiming to replace painful procedures.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

UK biotech Cytospire secures a major Series A to bring its novel pan-gamma delta T cell engagers, targeting tough solid tumors, into clinical trials.

A top European fertility network is rolling out AI to select embryos, promising higher success rates but sparking debate on the future of data-driven parenthood.